Abstract :
[en] Local treatment using drug loaded implants allows decreasing seric concentrations of the active ingredient with the purpose of limiting side effects and reaching perfect observance. Nowadays, some diseases are already treated with implants, but generally, by subcutaneous or intra vaginal implantation. In this work, a new implant device dedicated to the intra-peritoneal cavity was developed. For this purpose, a core-membrane polymer implant was selected. We propose an original method to determine the most appropriate membrane to control the release based on the use of Franz cells. The ability of the implant to release a constant quantity of an active ingredient will be assessed by testing implants in vitro. Finally, intra peritoneal cavity and subcutaneous in vivo implantation has been achieved in order to confirm the controlled and local release of the active ingredient.
Commentary :
Special thanks are due to ATC (Liège, Belgium) for the Pharmacokinetics studies. Thanks are due to the Walloon Region for the research grant (WALEO 2) and to Pierre Lebrun for the statistical studies.
Scopus citations®
without self-citations
4